Established Market Presence Chartwell Pharmaceuticals has a strong position as the 5th largest US generic pharmaceutical manufacturer with over 1,100 Orange Book listings and more than 700 commercialized NDCs. This indicates a broad product portfolio, presenting opportunities for partners seeking reliable manufacturing of a wide range of generics.

Recent Expansion & Investment The company's recent acquisitions, including Hemlock Drive Systems, and investments in new dosage forms like Unit Dose Liquids and Semi-Solids, signal active growth and diversification efforts. These developments create prospects to offer innovative technology solutions and support for product pipeline expansion.

US Manufacturing Focus With manufacturing facilities in Congers, Carmel, and Amityville, and a commitment to TAA and BAA compliance, Chartwell emphasizes domestic production suitable for global clients. This focus appeals to companies prioritizing US-made products for quality and regulatory compliance, opening doors for partnership in compliant manufacturing.

Trusted Expertise The company's experienced leadership and technical staff, along with cGMP compliant facilities over 25 years, position it as a reliable partner for complex manufacturing, research, and analytical services—ideal for collaborations on high-quality, trusted pharmaceutical products.

Growth & Opportunity With revenues estimated between $50 million and $100 million and continuous growth through plant expansions and broadening product lines, Chartwell offers scalable opportunities for suppliers and service providers looking to support a growing pharmaceutical manufacturing enterprise committed to innovation and quality.